H. Futami

发表

UCN-01, 7-hydroxyl-staurosporine, inhibits kinase activity of cyclin-dependent kinases and reduces the phosphorylation of the retinoblastoma susceptibility gene product in A549 human lung cancer cell line.

J. Takahara, K. Kawakami, H. Futami, 1996, Biochemical and biophysical research communications.

Two Germline Missense Mutations at Codons 804 and 806 of the RET Proto‐oncogene in the Same Allele in a Patient with Multiple Endocrine Neoplasia Type 2B without Codon 918 Mutation

A. Miyauchi, H. Futami, K. Sugano, 1999, Japanese journal of cancer research : Gann.

Effects of the combination of acivicin and cis-diamminedichloroplatinum(II) on thymidylate synthesis of A549 lung cancer cells.

Y. Yamaji, H. Futami, N. Yamauchi, 1989, Biochemical and biophysical research communications.

Prevention of acute chemotherapy-induced death in mice by recombinant human interleukin 1: protection from hematological and nonhematological toxicities.

D. Longo, F. Ruscetti, G. Damia, 1992, Cancer research.

In vivo distribution and cytokine gene expression by enriched mouse LAK effector cells

H. Young, H. Futami, T. Back, 1991, Biotherapy.

RET protein promotes non‐adherent growth of NB‐39‐nu neuroblastoma cell line

R. Sakai, H. Futami, 2009, Cancer science.

A two-hit model for development of multiple endocrine neoplasia type 2B by RET mutations.

M. Ichihara, Shanlou Qiao, A. Miyauchi, 2000, Biochemical and biophysical research communications.

A Large Germline Deletion of the MEN1 Gene in a Family with Multiple Endocrine Neoplasia Type 1

H. Futami, S. Shimizu, T. Obara, 1998, Japanese journal of cancer research : Gann.

Murine Renal Cancer (Renca) Model: Background and Preclinical Studies

T. Sayers, H. Young, H. Futami, 1991 .

[A case of idiopathic interstitial pneumonia with marked increase of serum CA-19-9].

Y. Yamaji, H. Futami, T. Shiotani, 1988, Nihon Kyobu Shikkan Gakkai zasshi.

[A case of pulmonary tuberculosis in a long-term survivor with small cell carcinoma of the lung].

J. Fujita, Y. Yamaji, H. Futami, 1989, Nihon Kyobu Shikkan Gakkai zasshi.

Comparison of vindesine plus cisplatin or vindesine plus mitomycin in the treatment of advanced non-small cell lung cancer.

K. Eguchi, K. Tominaga, N. Saijo, 1985, Cancer treatment reports.

DNA testing for more sophisticated clinical management of multiple endocrine neoplasia type 2 (MEN 2)

H. Futami, 1998, Japanese journal of clinical oncology.

Suppression of natural killer activity in patients treated with cisplatin and methylprednisolone

K. Eguchi, K. Tominaga, N. Saijo, 2005, Journal of Cancer Research and Clinical Oncology.

Detection of cytotoxicity of freshly obtained lymphocytes and of lymphocytes activated with recombinant interleukin II (rIL-2) against lung cancer cell lines by human tumor clonogenic assay (HTCA).

N. Saijo, A. Hamburger, H. Futami, 1986, European journal of cancer & clinical oncology.

Allelic loss of DNA locus of the RET proto-oncogene in small cell lung cancer.

H. Futami, S. Egawa, T. Tsukada, 2003, Cancer letters.

Inhibition of lymphatic metastasis in a syngeneic rat fibrosarcoma model by an angiogenesis inhibitor, AGM-1470.

H. Futami, S. Egawa, K. Yamaguchi, 1996, Invasion & metastasis.

Cytokine induction and therapeutic synergy with interleukin-2 against murine renal and colon cancers by xanthenone-4-acetic acid derivatives.

H. Young, H. Futami, R. Wiltrout, 1992, Journal of immunotherapy : official journal of the Society for Biological Therapy.

Flavone acetic acid directly induces expression of cytokine genes in mouse splenic leukocytes but not in human peripheral blood leukocytes.

H. Young, H. Futami, J. Ortaldo, 1991, Cancer research.

Genotype-phenotype correlation of patients with multiple endocrine neoplasia type 2 in Japan.

A. Yoshimura, Kenichi Inoue, A. Miyauchi, 1998, Japanese journal of clinical oncology.

A Novel Somatic Point Mutation of the RET Proto‐oncogene in Tumor Tissues of Small Cell Lung Cancer Patients

M. Noguchi, S. Bandoh, H. Futami, 1995, Japanese journal of cancer research : Gann.

The role of angiogenesis in the tumor growth of Syrian hamster pancreatic cancer cell line HPD-NR.

H. Futami, S. Egawa, Y. Konishi, 1995, Gastroenterology.

Reversal of enzymic phenotype of thymidine metabolism in induced differentiation of U-937 cells.

J. Fujita, Y. Yamaji, H. Futami, 1989, Cancer research.

Reversal of enzymic phenotype of thymidine metabolism in induced differentiation of HL-60 cells.

J. Fujita, Y. Yamaji, H. Futami, 1989, Leukemia research.

All-trans retinoic acid downregulates ALK in neuroblastoma cell lines and induces apoptosis in neuroblastoma cell lines with activated ALK.

R. Sakai, H. Futami, 2010, Cancer letters.

Chemoprotective effects of recombinant human IL-1 alpha in cyclophosphamide-treated normal and tumor-bearing mice. Protection from acute toxicity, hematologic effects, development of late mortality, and enhanced therapeutic efficacy.

D. Longo, F. Ruscetti, H. Futami, 1990, Journal of immunology.

Prospective Trial of Unilateral Surgery for Nonhereditary Medullary Thyroid Carcinoma in Patients without Germline RET Mutations

A. Miyauchi, Yasuhiro Ito, H. Futami, 2002, World Journal of Surgery.

Systemic alkalinization inhibits the ability of flavone acetic acid to augment natural killer activity, induce cytokine gene expression, and synergize with interleukin 2 for the treatment of murine renal cancer.

H. Futami, R. Wiltrout, R. Hornung, 1990, Cancer research.

A Novel Point Mutation of the RET Proto-oncogene in Small Cell Lung Carcinoma Cell Lines.

H. Futami, S. Egawa, K. Yamaguchi, 1994 .

Germline Mutations of the MEN1 Gene in Japanese Kindred with Multiple Endocrine Neoplasia Type 1

T. Kameya, H. Futami, S. Shimizu, 1997, Japanese journal of cancer research : Gann.

Cytokine-Based Combined Modality Approaches to the Treatment of Murine Renal Cancer

D. Longo, F. Ruscetti, G. Damia, 1992 .

Phase II study of cis-diamminedichloroplatinum in patients with non-small cell lung cancer.

K. Eguchi, K. Tominaga, N. Saijo, 1985, Japanese journal of cancer research : Gann.

Effects of recombinant transforming growth factor-beta 1 on hematologic recovery after treatment of mice with 5-fluorouracil.

D. Longo, F. Ruscetti, G. Damia, 1991, Journal of immunology.

A Novel Somatic Mutation in the RET Proto‐oncogene in Familial Medullary Thyroid Carcinoma with a Germline Codon 768 Mutation

A. Miyauchi, H. Futami, S. Egawa, 1997, Japanese journal of cancer research : Gann.

Unilateral Surgery Supported by Germline RET Oncogene Mutation Analysis in Patients with Sporadic Medullary Thyroid Carcinoma

A. Miyauchi, H. Futami, Kaoru Kobayashi, 2000, World Journal of Surgery.

Serial plasma carcinoembryonic antigen measurement for monitoring patients with advanced lung cancer during chemotherapy

K. Eguchi, K. Tominaga, K. Suemasu, 1986, Cancer.

FUS/TLS-CHOP chimeric transcripts in liposarcoma tissues.

H. Futami, T. Shimoda, S. Egawa, 1995, Japanese Journal of Clinical Oncology.

Differences of host immune response and of sensitivity to chemotherapeutic agents between two clones of rat fibrosarcoma with different metastatic potential.

N. Saijo, A. Hamburger, H. Futami, 1986, Japanese journal of cancer research : Gann.

Phase II study of vindesine in patients with non-small cell lung cancer.

K. Eguchi, K. Tominaga, N. Saijo, 1985, Japanese journal of cancer research : Gann.

Phase II of ACNU for non-small cell lung cancer.

K. Eguchi, K. Tominaga, N. Saijo, 1985, European journal of cancer & clinical oncology.

Preliminary phase II study of adriamycin (ADM) in patients with non-small cell lung cancer (NSCLC).

K. Eguchi, K. Tominaga, N. Saijo, 1985, Japanese Journal of Clinical Oncology.

A family of multiple endocrine neoplasia type 2A with the RET proto-oncogene mutation in codon 618 (Cys-->Arg).

H. Futami, Y. Naomoto, H. Isozaki, 2001, Japanese journal of clinical oncology.